Financing channel feed – Endpoints News

Financing channel feed

Upsized offering delivers $100M payoff to argenx as another biotech joins the IPO parade

9 years ago

G1 Therapeutics joins a growing biotech winners circle with $105M IPO

9 years ago

With a $42M raise and a reverse merger, Synlogic makes a quick flip onto Nasdaq

9 years ago

Genoa Pharma grabs a $62M A round to back its oral IPF drug Aerodone

9 years ago

From Biogen’s buy side to biotech CEO: Josh Mandel-Brehm joins the Polaris family as a serial entrepreneur in the making

9 years ago

Armed with a $435M bankroll, Polaris looks to the next wave of biotech startups

9 years ago

Jeremy Levin joins the biotech IPO rush, gaining $75M for Ovid’s R&D game plan

9 years ago

Two new IPOs -- upsized and over the range -- score $226M and signal a possible comeback for biotech

9 years ago

GenSight vet Combal grabs $40M from Novartis, Roche group for second-wave gene therapy biotech

9 years ago

Five months, $98.5M and a PhII drug from Novartis later, Magenta Therapeutics is flooring it

9 years ago

Way over budget and years late — AstraZeneca’s massive HQ project offers a troubling symbol

9 years ago

Shanghai-based EpimAb Bio grows global roots with $25M A round and a key assist by Robert Kamen

9 years ago

Ex-Dendreon chief Mitch Gold steers his way back to the public markets, looking to jumpstart a new clinical program

9 years ago

Hey Pfizer, Novartis and Eli Lilly. G1 Therapeutics says it can beat all of you in its $115M IPO

9 years ago

SV debuts a new, $400M fund with a big focus on biotech startups

9 years ago

Megadeals keep investments up in lifesci’s Q1, but the tempo continues to slow for biotech

9 years ago

Jeremy Levin spotlights a trendy new way to build a pipeline with his $86M IPO for Ovid

9 years ago

A serial biotech startup team is back in business, armed with $40M and a focus on NASH

9 years ago

Frequency Therapeutics gets a $32M startup round to help fine tune its hearing loss drug R&D

9 years ago

In the hunt for a $100M IPO, Biohaven polishes up discards from Bristol-Myers, AstraZeneca

9 years ago

Armed with deals, dollars and the promise of upcoming data, Zymeworks files $75M IPO

9 years ago

Solid Biosciences appears to be prepping for an IPO with $50M round for Duchenne gene therapy

9 years ago

Money, brains and ambition: Third Rock startup Tango launches with $55M and a stellar crew of scientific advisers

9 years ago

Virtual biotech Antiva sets out on a big R&D quest, armed with a $22M round for an HPV therapy

9 years ago

First page Previous page 140 141 142143144 145 146 Next page Last page